Cravath’s New York Office Moves to Two Manhattan West
Cravath represented Vaxxinity, Inc. in connection with its initial public offering. Vaxxinity is a U.S.‑based global biotechnology company pioneering a new class of immunotherapeutic vaccines to democratize health. Shares began trading on November 11, 2021 on The Nasdaq Global Market.
The Cravath team was led by partners Joseph D. Zavaglia and Nicholas A. Dorsey and included associates Virginia M. Anderson, Andrew J. Astore and Nicholas A. DiStefano on capital markets matters; partners John W. White and Michael L. Arnold and associates William D. Podurgiel and Ashley Gust on corporate governance matters; partner Christopher K. Fargo and associate Leon B. Dalezman on tax matters; partner Matthew J. Bobby, practice area attorney Arian Mossanenzadeh and associate Anna Mikaelyan on executive compensation and benefits matters; and partners David J. Kappos and Sasha Rosenthal‑Larrea and associates Matthew L. Ploszek and Pedraam Mirzanian on intellectual property matters. Colin L. Harvey also worked on capital markets matters.
Deals & Cases
April 15, 2024
Cravath, together with Hengeler Mueller, represented Douglas AG in connection with its €890 million initial public offering of ordinary bearer shares. The DOUGLAS Group is a leading omnichannel premium beauty destination in Europe. The shares were listed on the Frankfurt Stock Exchange (Prime Standard). The transaction closed on March 25, 2024.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.